GeneDx (WGS) announced that the FDA has granted breakthrough device designation for its whole genome and exome tests associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx initiated with a Buy at Canaccord
- WGS, PONY, QSI, SLMT: Cathie Wood Snaps Up Biotech and AI Stocks, Trims Stake in a Semiconductor Name
- GeneDx announces Mimi Lee as chief precision medicine officer
- GeneDx selected by Florida State University as partner for Sunshine Genetics Act
- DASH, DE, BABA: Cathie Wood Loads Up on DoorDash, Deere & Alibaba, Trims Stakes in ADPT and Others